Search

Your search keyword '"Rutgeerts, Paul"' showing total 2,465 results
Start Over Author "Rutgeerts, Paul"
2,465 results on '"Rutgeerts, Paul"'

6. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis

Author

Telesco, Shannon E., Brodmerkel, Carrie, Zhang, Hongyan, Kim, Lilianne (Lee-Lian), Johanns, Jewel, Mazumder, Abhijit, Li, Katherine, Baribaud, Frédéric, Curran, Mark, Strauss, Richard, Paxson, Bethany, Plevy, Scott, Davison, Timothy, Knight, Laura, Dibben, Sian, Schreiber, Stefan, Sandborn, William, Rutgeerts, Paul, Siegel, Corey A., Reinisch, Walter, and Greenbaum, Linda E.

Published
2018
Full Text
View/download PDF

9. Association Between Variants of PRDM1 and NDP52 and Crohn's Disease, Based on Exome Sequencing and Functional Studies

Author

Ellinghaus, David, Zhang, Hu, Zeissig, Sebastian, Lipinski, Simone, Till, Andreas, Jiang, Tao, Stade, Björn, Bromberg, Yana, Ellinghaus, Eva, Keller, Andreas, Rivas, Manuel A, Skieceviciene, Jurgita, Doncheva, Nadezhda T, Liu, Xiao, Liu, Qing, Jiang, Fuman, Forster, Michael, Mayr, Gabriele, Albrecht, Mario, Häsler, Robert, Boehm, Bernhard O, Goodall, Jane, Berzuini, Carlo R, Lee, James, Andersen, Vibeke, Vogel, Ulla, Kupcinskas, Limas, Kayser, Manfred, Krawczak, Michael, Nikolaus, Susanna, Weersma, Rinse K, Ponsioen, Cyriel Y, Sans, Miquel, Wijmenga, Cisca, Strachan, David P, McArdle, Wendy L, Vermeire, Séverine, Rutgeerts, Paul, Sanderson, Jeremy D, Mathew, Christopher G, Vatn, Morten H, Wang, Jun, Nöthen, Markus M, Duerr, Richard H, Büning, Carsten, Brand, Stephan, Glas, Jürgen, Winkelmann, Juliane, Illig, Thomas, Latiano, Anna, Annese, Vito, Halfvarson, Jonas, D'Amato, Mauro, Daly, Mark J, Nothnagel, Michael, Karlsen, Tom H, Subramani, Suresh, Rosenstiel, Philip, Schreiber, Stefan, Parkes, Miles, and Franke, Andre

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Nutrition and Dietetics, Biotechnology, Genetics, Inflammatory Bowel Disease, Autoimmune Disease, Human Genome, Clinical Research, Digestive Diseases, Crohn's Disease, Aetiology, 2.1 Biological and endogenous factors, Oral and gastrointestinal, Inflammatory and immune system, Adolescent, Adult, Case-Control Studies, Colitis, Ulcerative, Crohn Disease, Exome, Female, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Male, Mutation, Missense, Nuclear Proteins, Polymorphism, Single Nucleotide, Positive Regulatory Domain I-Binding Factor 1, Quantitative Trait Loci, Repressor Proteins, Young Adult, Whole-Exome Sequencing, Complex Disease, CD, Crohn’s disease, GWAS, IBD, IFN, NF-κB, PBL, PBMC, SNP, SNV, TLR, Toll-like receptor, UC, WT, eQTL, expression quantitative trait locus, genome-wide association studies, inflammatory bowel disease, interferon, nuclear factor κB, peripheral blood lymphocyte, peripheral blood mononuclear cell, qRT-PCR, quantitative reverse-transcription polymerase chain reaction, single nucleotide polymorphism, single nucleotide variant, ulcerative colitis, wild-type, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Background & aimsGenome-wide association studies (GWAS) have identified 140 Crohn's disease (CD) susceptibility loci. For most loci, the variants that cause disease are not known and the genes affected by these variants have not been identified. We aimed to identify variants that cause CD through detailed sequencing, genetic association, expression, and functional studies.MethodsWe sequenced whole exomes of 42 unrelated subjects with CD and 5 healthy subjects (controls) and then filtered single nucleotide variants by incorporating association results from meta-analyses of CD GWAS and in silico mutation effect prediction algorithms. We then genotyped 9348 subjects with CD, 2868 subjects with ulcerative colitis, and 14,567 control subjects and associated variants analyzed in functional studies using materials from subjects and controls and in vitro model systems.ResultsWe identified rare missense mutations in PR domain-containing 1 (PRDM1) and associated these with CD. These mutations increased proliferation of T cells and secretion of cytokines on activation and increased expression of the adhesion molecule L-selectin. A common CD risk allele, identified in GWAS, correlated with reduced expression of PRDM1 in ileal biopsy specimens and peripheral blood mononuclear cells (combined P = 1.6 × 10(-8)). We identified an association between CD and a common missense variant, Val248Ala, in nuclear domain 10 protein 52 (NDP52) (P = 4.83 × 10(-9)). We found that this variant impairs the regulatory functions of NDP52 to inhibit nuclear factor κB activation of genes that regulate inflammation and affect the stability of proteins in Toll-like receptor pathways.ConclusionsWe have extended the results of GWAS and provide evidence that variants in PRDM1 and NDP52 determine susceptibility to CD. PRDM1 maps adjacent to a CD interval identified in GWAS and encodes a transcription factor expressed by T and B cells. NDP52 is an adaptor protein that functions in selective autophagy of intracellular bacteria and signaling molecules, supporting the role of autophagy in the pathogenesis of CD.

Published
2013

10. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

Author

Rutgeerts, Paul J, Fedorak, Richard N, Hommes, Daan W, Sturm, Andreas, Baumgart, Daniel C, Bressler, Brian, Schreiber, Stefan, Mansfield, John C, Williams, Marna, Tang, Meina, Visich, Jennifer, Wei, Xiaohui, Keir, Mary, Luca, Diana, Danilenko, Dimitri, Egen, Jackson, and O'Byrne, Sharon

Subjects
Inflammatory Bowel Disease, Biotechnology, Clinical Trials and Supportive Activities, Clinical Research, Digestive Diseases, Autoimmune Disease, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Adult, Aged, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Colitis, Ulcerative, Dose-Response Relationship, Drug, Double-Blind Method, Female, Gastrointestinal Agents, Humans, Infusions, Intravenous, Injections, Subcutaneous, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Young Adult, Etrolizumab, rhuMAb 7, ulcerative colitis, drug development, safety, pharmacokinetics, IBD clinical, IBD basic research, IBD, IBD models, apoptosis, cell cycle, immunology, inflammatory bowel disorders, dendritic cells, Crohn's disease, cytokines, genetics, signal transduction, IBD-genetics, antibody targeted therapy, arthritis, autoimmune disease, integrins, IBD–genetics, rhuMAb β7, Clinical Sciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology
Abstract

ObjectiveEtrolizumab (rhuMAb β7, anti-β7, PRO145223) is a humanised monoclonal antibody targeting the β7 subunit of the heterodimeric integrins α4β7 and αEβ7, which are implicated in leucocyte migration and retention in ulcerative colitis (UC). This randomised phase I study evaluated the safety and pharmacology of etrolizumab in patients with moderate to severe UC.DesignIn the single ascending dose (SAD) stage, etrolizumab (0.3, 1.0, 3.0, 10 mg/kg intravenous, 3.0 mg/kg subcutaneous (SC) or placebo) was administered 4:1 (n=25) in each cohort. In the multiple dose (MD) stage, new patients received monthly etrolizumab (0.5 mg/kg SC (n=4), 1.5 mg/kg SC (n=5), 3.0 mg/kg SC (n=4), 4.0 mg/kg intravenous (n=5)) or placebo (n=5). The pharmacokinetics was studied and Mayo Clinic Score evaluated at baseline, day 29 (SAD), and days 43 and 71 (MD).ResultsIn the SAD stage, there were no dose limiting toxicities, infusion or injection site reactions. Two impaired wound healing serious adverse events occurred in two patients receiving etrolizumab. In the MD stage, there were no dose limiting toxicities, and no infusion or injection site reactions. Headache was the most common adverse event, occurring more often in etrolizumab patients. Antietrolizumab antibodies were detected in two subjects. The duration of β7 receptor full occupancy was dose related. A clinical response was observed in 12/18 patients, and clinical remission in 3/18 patients treated with etrolizumab in the MD stage, compared with 4/5 and 1/5 placebo patients, respectively.ConclusionEtrolizumab is well tolerated in moderate to severe UC. Further investigation is warranted.

Published
2013

11. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

Author

Anderson, Carl A, Boucher, Gabrielle, Lees, Charlie W, Franke, Andre, D'Amato, Mauro, Taylor, Kent D, Lee, James C, Goyette, Philippe, Imielinski, Marcin, Latiano, Anna, Lagacé, Caroline, Scott, Regan, Amininejad, Leila, Bumpstead, Suzannah, Baidoo, Leonard, Baldassano, Robert N, Barclay, Murray, Bayless, Theodore M, Brand, Stephan, Büning, Carsten, Colombel, Jean-Frédéric, Denson, Lee A, De Vos, Martine, Dubinsky, Marla, Edwards, Cathryn, Ellinghaus, David, Fehrmann, Rudolf SN, Floyd, James AB, Florin, Timothy, Franchimont, Denis, Franke, Lude, Georges, Michel, Glas, Jürgen, Glazer, Nicole L, Guthery, Stephen L, Haritunians, Talin, Hayward, Nicholas K, Hugot, Jean-Pierre, Jobin, Gilles, Laukens, Debby, Lawrance, Ian, Lémann, Marc, Levine, Arie, Libioulle, Cecile, Louis, Edouard, McGovern, Dermot P, Milla, Monica, Montgomery, Grant W, Morley, Katherine I, Mowat, Craig, Ng, Aylwin, Newman, William, Ophoff, Roel A, Papi, Laura, Palmieri, Orazio, Peyrin-Biroulet, Laurent, Panés, Julián, Phillips, Anne, Prescott, Natalie J, Proctor, Deborah D, Roberts, Rebecca, Russell, Richard, Rutgeerts, Paul, Sanderson, Jeremy, Sans, Miquel, Schumm, Philip, Seibold, Frank, Sharma, Yashoda, Simms, Lisa A, Seielstad, Mark, Steinhart, A Hillary, Targan, Stephan R, van den Berg, Leonard H, Vatn, Morten, Verspaget, Hein, Walters, Thomas, Wijmenga, Cisca, Wilson, David C, Westra, Harm-Jan, Xavier, Ramnik J, Zhao, Zhen Z, Ponsioen, Cyriel Y, Andersen, Vibeke, Torkvist, Leif, Gazouli, Maria, Anagnou, Nicholas P, Karlsen, Tom H, Kupcinskas, Limas, Sventoraityte, Jurgita, Mansfield, John C, Kugathasan, Subra, Silverberg, Mark S, Halfvarson, Jonas, Rotter, Jerome I, Mathew, Christopher G, Griffiths, Anne M, Gearry, Richard, Ahmad, Tariq, Brant, Steven R, and Chamaillard, Mathias

Subjects
Biological Sciences, Genetics, Autoimmune Disease, Human Genome, Crohn's Disease, Digestive Diseases, Nutrition, Inflammatory Bowel Disease, Prevention, Oral and gastrointestinal, Colitis, Ulcerative, Crohn Disease, Genome-Wide Association Study, Humans, Risk, Medical and Health Sciences, Developmental Biology, Agricultural biotechnology, Bioinformatics and computational biology
Abstract

Genome-wide association studies and candidate gene studies in ulcerative colitis have identified 18 susceptibility loci. We conducted a meta-analysis of six ulcerative colitis genome-wide association study datasets, comprising 6,687 cases and 19,718 controls, and followed up the top association signals in 9,628 cases and 12,917 controls. We identified 29 additional risk loci (P < 5 × 10(-8)), increasing the number of ulcerative colitis-associated loci to 47. After annotating associated regions using GRAIL, expression quantitative trait loci data and correlations with non-synonymous SNPs, we identified many candidate genes that provide potentially important insights into disease pathogenesis, including IL1R2, IL8RA-IL8RB, IL7R, IL12B, DAP, PRDM1, JAK2, IRF5, GNA12 and LSP1. The total number of confirmed inflammatory bowel disease risk loci is now 99, including a minimum of 28 shared association signals between Crohn's disease and ulcerative colitis.

Published
2011

12. Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease.

Author

Koslowski, Maureen J, Kübler, Irmgard, Chamaillard, Mathias, Schaeffeler, Elke, Reinisch, Walter, Wang, Guoxing, Beisner, Julia, Teml, Alexander, Peyrin-Biroulet, Laurent, Winter, Stefan, Herrlinger, Klaus R, Rutgeerts, Paul, Vermeire, Séverine, Cooney, Rachel, Fellermann, Klaus, Jewell, Derek, Bevins, Charles L, Schwab, Matthias, Stange, Eduard F, and Wehkamp, Jan

Subjects
Paneth Cells, Ileum, Humans, Crohn Disease, Genetic Predisposition to Disease, Sequence Analysis, DNA, Genotype, Linkage Disequilibrium, Polymorphism, Single Nucleotide, Alleles, Adolescent, Adult, Female, Male, TCF Transcription Factors, Nod2 Signaling Adaptor Protein, Promoter Regions, Genetic, Genetic Variation, Young Adult, Transcription Factor 7-Like 2 Protein, Polymorphism, Single Nucleotide, Promoter Regions, Genetic, Sequence Analysis, DNA, General Science & Technology
Abstract

Reduced expression of Paneth cell antimicrobial alpha-defensins, human defensin (HD)-5 and -6, characterizes Crohn's disease (CD) of the ileum. TCF-4 (also named TCF7L2), a Wnt signalling pathway transcription factor, orchestrates Paneth cell differentiation, directly regulates the expression of HD-5 and -6, and was previously associated with the decrease of these antimicrobial peptides in a subset of ileal CD. To investigate a potential genetic association of TCF-4 with ileal CD, we sequenced 2.1 kb of the 5' flanking region of TCF-4 in a small group of ileal CD patients and controls (n = 10 each). We identified eight single nucleotide polymorphisms (SNPs), of which three (rs3814570, rs10885394, rs10885395) were in linkage disequilibrium and found more frequently in patients; one (rs3814570) was thereby located in a predicted regulatory region. We carried out high-throughput analysis of this SNP in three cohorts of inflammatory bowel disease (IBD) patients and controls. Overall 1399 healthy individuals, 785 ulcerative colitis (UC) patients, 225 CD patients with colonic disease only and 784 CD patients with ileal involvement were used to determine frequency distributions. We found an association of rs3814570 with ileal CD but neither with colonic CD or UC, in a combined analysis (allele positivity: OR 1.27, 95% CI 1.07 to 1.52, p = 0.00737), which was the strongest in ileal CD patients with stricturing behaviour (allele frequency: OR 1.32, 95% CI 1.08 to1.62, p = 0.00686) or an additional involvement of the upper GIT (allele frequency: OR 1.38, 95% CI 1.03 to1.84, p = 0.02882). The newly identified genetic association of TCF-4 with ileal CD provides evidence that the decrease in Paneth cell alpha-defensins is a primary factor in disease pathogenesis.

Published
2009

13. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

Author

Colombel, Jean-Frederic, Panaccione, Remo, Bossuyt, Peter, Lukas, Milan, Baert, Filip, Vaňásek, Tomas, Danalioglu, Ahmet, Novacek, Gottfried, Armuzzi, Alessandro, Hébuterne, Xavier, Travis, Simon, Danese, Silvio, Reinisch, Walter, Sandborn, William J, Rutgeerts, Paul, Hommes, Daniel, Schreiber, Stefan, Neimark, Ezequiel, Huang, Bidan, Zhou, Qian, Mendez, Paloma, Petersson, Joel, Wallace, Kori, Robinson, Anne M, Thakkar, Roopal B, and D'Haens, Geert

Published
2017
Full Text
View/download PDF

29. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

Author

Vermeire, Séverine, O'Byrne, Sharon, Keir, Mary, Williams, Marna, Lu, Timothy T, Mansfield, John C, Lamb, Christopher A, Feagan, Brian G, Panes, Julian, Salas, Azucena, Baumgart, Daniel C, Schreiber, Stefan, Dotan, Iris, Sandborn, William J, Tew, Gaik W, Luca, Diana, Tang, Meina T, Diehl, Lauri, Eastham-Anderson, Jeffrey, De Hertogh, Gert, Perrier, Clementine, Egen, Jackson G, Kirby, John A, van Assche, Gert, and Rutgeerts, Paul

Published
2014
Full Text
View/download PDF

33. Infliximab Therapy

Author

Vermeire, Sèverine, Assche, Gert Van, Rutgeerts, Paul, Mamula, Petar, editor, Markowitz, Jonathan E., editor, and Baldassano, Robert N., editor

Published
2008
Full Text
View/download PDF

40. Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC

Author

Machiels, Kathleen, Sabino, João, Vandermosten, Leen, Joossens, Marie, Arijs, Ingrid, de Bruyn, Magali, Eeckhaut, Venessa, Van Assche, Gert, Ferrante, Marc, Verhaegen, Jan, Van Steen, Kristel, Van Immerseel, Filip, Huys, Geert, Verbeke, Kristin, Wolthuis, Albert, de Buck Van Overstraeten, Anthony, DʼHoore, Andre, Rutgeerts, Paul, and Vermeire, Séverine

Published
2017
Full Text
View/download PDF

44. Abatacept for Crohn's Disease and Ulcerative Colitis

Author

Sandborn, William J., Colombel, Jean–Frederic, Sands, Bruce E., Rutgeerts, Paul, Targan, Stephan R., Panaccione, Remo, Bressler, Brian, Geboes, Karl, Schreiber, Stefan, Aranda, Richard, Gujrathi, Sheila, Luo, Allison, Peng, Yun, Salter–Cid, Luisa, and Hanauer, Stephen B.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results